Skip to content
value.today
TherapeuticsMD, Inc. logo

TherapeuticsMD, Inc.

🇺🇸 Boca Raton, Florida, USAPharmaceuticalsFounded 2010
Total raised
$9 M
1 round on record
Latest round
$9 M
Sep 2012
First round on record
Sep 2012
Today
Went public
See the company page

TherapeuticsMD, Inc. is listed today as TherapeuticsMD, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of TherapeuticsMD, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2023$1 MPrivate placement after listingUnder $2 million

TherapeuticsMD, Inc.: Private sale, Jun 2023

Investors in this round

2 investors had bought by the notice of Jul 11, 2023: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $5 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Marlan C. Walker · Executive Officer
  • Michael C. Donegan · Executive Officer
  • Cooper C. Collins · Director
  • Gail G. Naughton · Director
  • Justin C. Roberts · Director
  • Tommy G. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Pursuant to a Subscription Agreement with Rubric Capital Management LP, the Company may sell, at the Company's election, up to an aggregate of 5,000,000 shares of the Company's common stock, at an aggregate purchase price of up to $5,000,000.”

Signed by Marlan Walker, Chief Executive Officer. Newest notice filed Jul 11, 2023. Read the notice at the SEC.

equitySEC
Oct 2022$7 MPrivate placement after listing$2 to $10 million

TherapeuticsMD, Inc.: Private sale, Oct 2022

Investors in this round

6 investors had bought by the notice of Nov 14, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$350,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian A. Bernick · Executive Officer
  • Mark A. Glickman · Executive Officer
  • Marlan A. Walker · Executive Officer
  • Michael C. Donegan · Executive Officer
  • Angus C. Russell · Director
  • Cooper C. Collins · Director
  • Gail C. Naughton · Director
  • Jules A. Musing · Director
  • Justin A. Roberts · Director
  • Karen A. Ling · Director
  • Paul C. Bisaro · Director
  • Tommy G. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Greenhill & Co. LLC (CRD 40290) · New York, New YorkSold in NY

Signed by Marlan Walker, General Counsel. Newest notice filed Nov 14, 2022. Read the notice at the SEC.

equity, optionsSEC
Sep 2022$7 MPrivate placement after listing$2 to $10 million

TherapeuticsMD, Inc.: Private sale, Sep 2022

Investors in this round

6 investors had bought by the notice of Oct 17, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$350,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian A. Bernick · Executive Officer
  • Mark A. Glickman · Executive Officer
  • Marlan A. Walker · Executive Officer
  • Michael C. Donegan · Executive Officer
  • Angus C. Russell · Director
  • Cooper C. Collins · Director
  • Gail C. Naughton · Director
  • Jules A. Musing · Director
  • Justin A. Roberts · Director
  • Karen A. Ling · Director
  • Paul C. Bisaro · Director
  • Tommy G. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Greenhill & Co. LLC (CRD 40290) · New York, New YorkSold in NY

Signed by Marlan Walker, General Counsel. Newest notice filed Oct 17, 2022. Read the notice at the SEC.

equity, optionsSEC
Jul 2022$15 MPrivate placement after listing$10 to $50 million

TherapeuticsMD, Inc.: Private sale, Jul 2022

Investors in this round

6 investors had bought by the notice of Aug 16, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$750,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Hugh O'Dowd · Executive Officer, Director
  • Mark A. Glickman · Executive Officer
  • Marlan A. Walker · Executive Officer
  • Michael C. Donegan · Executive Officer
  • Angus C. Russell · Director
  • Cooper C. Collins · Director
  • Gail C. Naughton · Director
  • Jules A. Musing · Director
  • Karen A. Ling · Director
  • Paul C. Bisaro · Director
  • Tommy G. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Greenhill & Co. LLC (CRD 40290) · New York, New YorkSold in NY

Signed by Marlan Walker, General Counsel. Newest notice filed Aug 16, 2022. Read the notice at the SEC.

equity, optionsSEC
Aug 2020$8 MPrivate placement after listing$2 to $10 million

TherapeuticsMD, Inc.: Private sale, Aug 2020

Investors in this round

3 investors had bought by the notice of Aug 14, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Edward L. Borkowski · Executive Officer
  • James C. D'Arecca · Executive Officer
  • John C.K. Milligan, IV · Executive Officer
  • Marlan D. Walker · Executive Officer
  • Michael L. Donegan · Executive Officer
  • Robert G. Finizio · Executive Officer, Director
  • Angus C. Russell · Director
  • Cooper C. Collins · Director
  • Gail K. Naughton · Director
  • J. Martin Carroll · Director
  • Jules A. Musing · Director
  • Karen L. Ling · Director
  • Paul M. Bisaro · Director
  • Tommy G. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents the approximate value of the warrants to purchase common stock issued.”

Signed by James C. D'Arecca, Chief Financial Officer. Newest notice filed Aug 14, 2020. Read the notice at the SEC.

optionsSEC
Sep 2012$9 MNo. 1$2 to $10 million

TherapeuticsMD, Inc.: Raise no. 1, Sep 2012

Investors in this round

8 investors had bought by the notice of Oct 10, 2012: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$552,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian L. Bernick, M.D. · Executive Officer, Director
  • Daniel A. Cartwright · Executive Officer
  • John C.K. Milligan IV · Executive Officer, Director
  • Mitchell L. Krassan · Executive Officer
  • Robert G. Finizio · Executive Officer, Director
  • Cooper C. Collins · Director
  • Nicholas V. Segal · Director
  • Robert V. LaPenta, Jr. · Director
  • Samuel A. Greco · Director
  • Tommy G. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies & Company, Inc. (CRD 2347) · New York, New YorkSold in CA, CO, CT, FL, MA, NJ, NY, PA

Remarks in the notice

  • On fees: “The amount represents fees earned by Jefferies & Company, Inc. for its services as exclusive placement agent.”

Signed by Daniel A. Cartwright, Chief Financial Officer. Newest notice filed Oct 10, 2012. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • TherapeuticsMD, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2023).

    SEC Form D · Jul 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2023

Products and services#

No products or services of TherapeuticsMD, Inc. are on record.

Investors#

No investor of TherapeuticsMD, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding TherapeuticsMD, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by TherapeuticsMD, Inc.
NameRoleNamed in
Marlan C. WalkerExecutive officerJul 2023
Michael C. DoneganExecutive officerJul 2023
Brian A. BernickExecutive officerNov 2022
Mark A. GlickmanExecutive officerNov 2022
Marlan A. WalkerExecutive officerNov 2022
Hugh O'DowdExecutive officerAug 2022
Edward L. BorkowskiExecutive officerAug 2020
James C. D'AreccaExecutive officerAug 2020
John C.K. Milligan, IVExecutive officerAug 2020
Marlan D. WalkerExecutive officerAug 2020
Michael L. DoneganExecutive officerAug 2020
Robert G. FinizioExecutive officerAug 2020
Brian L. Bernick, M.D.Executive officerOct 2012
Daniel A. CartwrightExecutive officerOct 2012
John C.K. Milligan IVExecutive officerOct 2012
Mitchell L. KrassanExecutive officerOct 2012
Cooper C. CollinsDirectorJul 2023
Gail G. NaughtonDirectorJul 2023
Justin C. RobertsDirectorJul 2023
Tommy G. ThompsonDirectorJul 2023
Angus C. RussellDirectorNov 2022
Gail C. NaughtonDirectorNov 2022
Jules A. MusingDirectorNov 2022
Justin A. RobertsDirectorNov 2022
Karen A. LingDirectorNov 2022
Paul C. BisaroDirectorNov 2022
Hugh O'DowdDirectorAug 2022
Gail K. NaughtonDirectorAug 2020
J. Martin CarrollDirectorAug 2020
Karen L. LingDirectorAug 2020
Paul M. BisaroDirectorAug 2020
Robert G. FinizioDirectorAug 2020
Brian L. Bernick, M.D.DirectorOct 2012
John C.K. Milligan IVDirectorOct 2012
Nicholas V. SegalDirectorOct 2012
Robert V. LaPenta, Jr.DirectorOct 2012
Samuel A. GrecoDirectorOct 2012

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.